Introduction
============

Gastrointestinal stromal tumor (GIST) is the most common sarcoma of the digestive tract, with an estimated incidence of 11.0--21.0 per million worldwide.[@b1-cmar-10-6121],[@b2-cmar-10-6121] GIST ranges in malignancy from small nodules that pursuit a benign course to bulky sarcoma with metastatic potential. Metastasis occurs in 15%--50% of patients at the time of diagnosis, making complete resection difficult.[@b3-cmar-10-6121],[@b4-cmar-10-6121] For patients with localized high-risk GIST, despite complete resection, nearly 40% suffer tumor relapse within 2 years. The liver and peritoneum are the most common sites of metastasis, accounting for about 65% and 20% of the total, respectively.[@b3-cmar-10-6121]

Imatinib, a tyrosine kinase inhibitor (TKI), is the first-line treatment for advanced GIST. In clinical trials, it achieved high disease control rates and significantly prolonged survival.[@b5-cmar-10-6121],[@b6-cmar-10-6121] However, despite its potent efficacy, resistance occurs in nearly 50% of patients after a treatment of 2 years. The limitation of TKI therapy has prompted the reassessment of surgery for advanced GIST, but opinions differ. Some suggested that only patients with stable or limited progression disease on TKI therapy could benefit from debulking surgery,[@b7-cmar-10-6121] whereas others found that when complete resection could be achieved, even those with progressing disease would benefit.[@b8-cmar-10-6121] In a Korean study, however, tumor burden instead of surgery was found to be a predictor of survival.[@b9-cmar-10-6121]

However, those studies dealt with patients with metastases in different locations. But from an anatomical perspective, metastases in the liver are easier to define and assess than those in the peritoneum. This feature gives GIST liver metastases (GLM) greater possibility of complete resection, distinguishing it from other metastatic GIST. Indeed, in a European study, patients with GLM had higher rate of R0 resection and showed the longest survival.[@b10-cmar-10-6121] Therefore, GLM may represent a special subset of advanced GIST where surgery has a greater role to play.

Although there are some studies dealing with patients with GLM, their baseline values and treatment strategies varied greatly: some patients had previous metastasis before spreading to the liver, and some did not receive TKI therapy after the operation.[@b11-cmar-10-6121],[@b12-cmar-10-6121] These variations were associated with a poor survival.[@b13-cmar-10-6121] Therefore, it is necessary to reassess the value of surgery in this subset of patients with a more balanced dataset. The aim of this study was to determine whether metastasectomy improves the survival of patients with GLM in the era of TKI therapy.

Patients and methods
====================

Patient selection
-----------------

We reviewed patients with metastatic GIST who received surgery or other treatments in Sun Yat-sen University Cancer Center between January 1991 and December 2017. Pathological diagnoses were performed or confirmed in our center. This retrospective study was approved by the institutional review board of Sun Yat-sen University Cancer Center, and written informed consent was obtained from all patients.

A total of 102 patients with liver-only metastases were included in this study. They were defined as those with metastases restricted to the liver, regardless of whether or not experiencing further dissemination to other locations. Patients with previous metastasis to the peritoneum, lung, bone, or other organs were excluded. Of the 102 patients, 21 underwent surgery for liver metastases (surgical group), while the other 81 received TKI therapy alone (non-surgical group). According to the time of occurrence, liver metastasis was classified into synchronous and metachronous. Synchronous liver metastasis was defined as metastasis that occurred at diagnosis or within 3 months after the resection of primary tumor, while metachronous liver metastasis was defined as one that occurred beyond 3 months after the resection (RDDA2018000853).

Tumor characteristics
---------------------

Risk stratification for primary tumor was performed using NIH criteria in 51 (50%) patients who had no metastases at diagnosis.[@b22-cmar-10-6121] The first radiological reports that described liver metastases were retracted in 85 patients but were unavailable in the other 17. According to these reports, the extent of liver metastases was classified as limited, if there were less than three detectable diseases, or as generalized, if there were three or more. Diameters of the largest metastases were depicted in 79 patients, with a median of 4.4 cm (range 1.0--15.0 cm). Fifty-four patients were tested for mutational status of genes *C-KIT* and *PDGFRA* by using primary tumor.

Surgical management
-------------------

Liver metastasectomy was performed in our center or other hospitals. For patients with synchronous metastases, resection of primary tumor was performed concurrently. Surgical procedures for liver lesions included partial resection, subsegmentectomy, and segmentectomy. Radiofrequency ablation was applied for suspicious or unreachable lesions to achieve NED (no evidence of disease). For patients receiving preoperative imatinib, all surgeries were performed when the diseases were responsive or stable.

Systemic treatment
------------------

All patients received 400 mg/d imatinib as first-line treatment after the operation. When disease progressed, they were prescribed second-line regimen, either with high-dose imatinib (600 mg/d or 800 mg/d) or sunitinib (37.5 mg/d). CT scan was scheduled every 6 months. Evaluation of response was performed according to RECIST criteria.[@b23-cmar-10-6121]

End points and statistics
-------------------------

Progression-free survival (PFS) was defined as the time between liver metastasis and disease progression or death from any cause, whichever came first. Overall survival (OS) was calculated from the time of liver metastasis to the time of death from any cause. The comparison of clinicopathological parameters between surgical and non-surgical groups was performed using chi-squared or Mann--Whitney *U* test, as appropriate. Prognostic factors were analyzed by univariate logistic regression. Parameters with *P*\<0.1 were included into multivariate analysis. All survival curves were calculated using Kaplan--Meier methods. Two-sided *P*-value less than 0.05 was considered significant.

Results
=======

Demographic data
----------------

Demographic data are listed in [Table 1](#t1-cmar-10-6121){ref-type="table"}. A total of 102 patients were included into the study, with 71 (69.6%) males and 31 (30.4%) females. Twenty-one (20.1%) patients underwent surgery for liver metastases, while 81 (79.9%) patients were treated with TKI drugs. Fifty-one (51%) patients had synchronous metastases, and 51 (50%) had metachronous metastases. Twenty-four (28.2%) patients had metastases of less than three, while 61 (71.8%) had three or more metastases.

Comparison between surgical and nonsurgical groups
--------------------------------------------------

[Table 2](#t2-cmar-10-6121){ref-type="table"} shows clinicopathological features of surgical and non-surgical groups. The number of liver metastases differs significantly between the two groups. About 42.9% of patients in surgical group had metastases of less than three, while the rate was 22.1% in non-surgical group (*P*=0.011). A marked difference was noted in the size of metastases, with 10 (62.5%) and 31 (49.2%) patients having a largest metastases of less than 4.5 cm in diameter in the two groups, respectively, but the difference was not significant (*P*=0.342). There was no significant difference in sex, age, primary sites, metastatic phase, and response to imatinib.

For patients undergoing metastasectomy, 14 (66.5%) received preoperative imatinib, and all of them achieved partial response or standard disease. Surgical procedures included partial resection in eleven patients, partial resection+ ablation in four, subsegmentectomy in three, segmentectomy in three, and segmentectomy+ ablation in two. Fifteen patients had complete resection (R0 resection), and six patients achieved NED with the help of intraoperative radiofrequency ablation. Six patients experienced disease progression because of discontinuation of imatinib. All of them regained control after resuming imatinib, but five of them later developed resistance and were treated with second-line regimens ([Table 3](#t3-cmar-10-6121){ref-type="table"}).

Survival analysis
-----------------

Survival analysis is shown in [Figure 1](#f1-cmar-10-6121){ref-type="fig"}. The 3-year PFS rate was 77.5% in the surgical group and 65.5% in the non-surgical group (*P*=0.027), and the 5-year OS rate was 85.7% and 59.6% for the two groups, respectively (*P*=0.008). Notably, patients with metastases of less than three had longer PFS than those with three or more, with a 3-year PFS rate of 72.8% and 65.8%, respectively (*P*=0.019). But their difference in 5-year OS rate was not significant (91.7% vs 55.3%, *P*=0.08). One patient in the surgical group died from uremia that was considered unrelated to the treatment. In multivariate analysis, although there was a tendency that metastasectomy might be an independent factor of PFS and OS, the results were not significant (*P*=0.064 and 0.095, respectively). Neither surgery nor the number of metastases was an independent factor of survival ([Table 4](#t4-cmar-10-6121){ref-type="table"}).

Discussion
==========

In this study, we found that when combined with TKI therapy, metastasectomy significantly prolonged the survival of patients with GLM. Our study focused on a special subset of GIST patients from a single center and offered an insight into the role of surgery in this setting.

The advent of imatinib has made debulking surgery for advanced GIST controversial. However, there is evidence suggesting benefits of such surgery. One possible reason is that surgery can remove tumors that contain secondary mutations, making imatinib effective again for these patients. As suggested in previous studies, tumors progressing on TKI therapy were more likely to contain secondary mutations than those responsive to the treatment.[@b14-cmar-10-6121],[@b15-cmar-10-6121]

GLM represents a special subgroup of advanced GIST. Hepatic lesions are easier to identify than metastases to other organs, and therefore are more amenable to surgery. In 2016, researchers found that when complete resection is achieved, patients with GLM may benefit from surgery, with survival rate at 5 years exceeding 80%. But in that study, 10% of the patients had extra-hepatic metastases before surgery, and 25% did not receive TKI therapy after surgery, which was crucial for prolonging patient survival.[@b11-cmar-10-6121],[@b13-cmar-10-6121] In our study, all patients received TKI therapy after surgery. We confirmed that complete resection of liver metastases was associated with better PFS and OS. The 5-year OS rate in surgical group was 85.7%. This rate was comparable to that in localized GIST, where the rate was 85.3% for patients receiving imatinib for 1 year after complete resection.[@b16-cmar-10-6121] The promising result indicates that R0 surgery, when followed by continuous TKI therapy, may be curative for patients with GLM.

In six patients for whom complete resection was not feasible, we used radiofrequency ablation to destroy residual or suspicious lesions. All patients achieved NED, and none of them showed recurrence during follow-up. It follows that when NED is achievable, ablation can produce the same survival benefits as surgery does. The result was echoed by a previous study, in which patients with GLM had a 5-year OS rate of 87.7% after liver surgery combined with intraoperative ablation. Radiofrequency ablation was effective and safe for this group of patients.[@b17-cmar-10-6121],[@b18-cmar-10-6121]

Both surgery and ablation, or their combination, serve the purpose of reducing tumor burden to the greatest extent, leaving no visible tumor cell to develop resistance during subsequent TKI therapy. However, unlike patients with localized GIST, for whom optimal duration of adjuvant TKI therapy remains debatable, patients with GLM seem to have to maintain the treatment lifelong. In a stage III clinical study, Kanda et al compared the efficacy of surgery with imatinib for GIST patients with resectable hepatic lesions and found that all patients experienced tumor recurrence after R0 resection, with a median RFS of only 145 days and a 3-year RFS rate of 16.7%. Hence, it was concluded that surgery alone, even achieving R0, was not curative for patients with GLM. Imatinib remained the main treatment for this group of patients.[@b19-cmar-10-6121] In our study, six patients who had discontinued imatinib after the operation developed new lesions rapidly, while the others stayed tumor-free at the last follow-up. This contrast suggests that continuous TKI therapy may be more important than surgery for a long-term survival.

Several other factors may affect patient survival, including patient age, baseline performance status, and pretreatment tumor burden.[@b3-cmar-10-6121],[@b9-cmar-10-6121],[@b20-cmar-10-6121] In our study, patients with less tumors were associated with longer PFS and OS, which suggested that the survival advantage observed in the surgical group may be attributed to its lower tumor burden. However, some argued that tumor burden affects survival through its impact on resectability, and as long as complete resection can be achieved, the impact can be overridden by surgery.[@b10-cmar-10-6121]

Interestingly, unlike colorectal cancer liver metastasis, where synchronous metastasis is considered to be more aggressive, metastatic phase seems not to affect patient outcome in GIST. In our study, PFS and OS did not differ between the two phases. Similar result was observed in a previous study.[@b12-cmar-10-6121] One possible reason is that gene mutation weighs more heavily in the development and progression of GIST than in that of colorectal cancer, with secondary mutation found in as high as 80% of progressed GIST lesions.[@b14-cmar-10-6121] Another reason is that TKI therapy for GIST is far more effective than chemotherapy for colorectal cancer, and the impact of metastatic phase is overshadowed.

Our study has some limitations. First, as a retrospective study, selection bias is unavoidable. Patients with less metastases were more likely to be selected for surgery. Second, due to the scarcity of this population, our study had a small sample. Third, the credibility of the study is subject to patients' compliance with treatment protocol. Some patients did not receive regular radiological examination, which might postpone the documentation of progression, and some patients discontinued treatment without consultation, which might impair their long-term survival.[@b21-cmar-10-6121]

Conclusion
==========

When R0 resection can be achieved, surgery is recommended for patients with GLM, regardless of the extent of disease or the phase of metastasis. Future studies with larger dataset and more balanced information are warranted.
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###### 

Patient characteristics

  Parameters                                                        Cases (n=102)   Percent
  ----------------------------------------------------------------- --------------- ---------
  Sex                                                                               
   Male                                                             71              69.6
   Female                                                           31              30.4
  Age (years)                                                                       
   Median                                                           52              --
   Range                                                            17--83          --
   \<60                                                             74              72.5
   ≥60                                                              28              27.5
  Primary sites                                                                     
   Stomach                                                          38              37.3
   Duodenum                                                         12              11.8
   Intestine                                                        38              37.3
   Colon and rectum                                                 2               2.0
   Others                                                           12              11.8
  Risk stratification[a](#tfn1-cmar-10-6121){ref-type="table-fn"}                   
   Middle                                                           4               3.9
   High                                                             47              46.1
   Metastatic                                                       51              48.0
  Metastatic phase                                                                  
   Synchronous                                                      51              50.0
   Metachronous                                                     51              50.0
  No. of metastases[b](#tfn2-cmar-10-6121){ref-type="table-fn"}                     
   \<3                                                              24              28.2
   ≥3                                                               61              71.8
  Diameter (cm)[c](#tfn3-cmar-10-6121){ref-type="table-fn"}                         
   Mean                                                             4.4             --
   Range                                                            1.0--15.0       --
  Genotype[d](#tfn3a-cmar-10-6121){ref-type="table-fn"}                             
   C-KIT 11 exon                                                    42              77.8
   C-KIT 9 exon                                                     5               9.3
   Wild-type                                                        6               11.1
   PDGFRA                                                           1               1.9
  Treatment                                                                         
   Surgery                                                          21              20.1
   Non-surgery                                                      81              79.9

**Notes:**

Patients were stratified at diagnosis and according to NIH cretiria;

radiological assessment for liver metastases was not available in 17 patients;

diameters of the largest metastases, data not available in 23 patients;

genotype tests for primary tumor were not performed in 48 patients.

**Abbreviation:** NIH, National Institutes of Health.

###### 

Comparison of clinicopathological parameters between surgical and non-surgical groups

  Parameters                                                     Surgical group   Non-surgical group   *P*-value
  -------------------------------------------------------------- ---------------- -------------------- -----------
  Sex                                                                                                  
   Male                                                          11 (52.4)        60 (74.1)            0.054
   Female                                                        10 (47.6)        21 (25.9)            
  Age (years)                                                                                          
   \<60                                                          15 (71.4)        59 (72.8)            0.897
   ≥60                                                           6 (28.6)         22 (27.2)            
  No of metastases[a](#tfn5-cmar-10-6121){ref-type="table-fn"}                                         
   \<3                                                           9 (42.9)         15 (22.1)            0.011
   ≥3                                                            8 (38.1)         53 (77.9)            
  Diameter (cm)[b](#tfn6-cmar-10-6121){ref-type="table-fn"}                                            
   \<4.5                                                         10 (62.5)        31 (49.2)            0.342
   ≥4.5                                                          6 (37.5)         32 (50.8)            
  Primary sites                                                                                        
   Stomach                                                       8 (38.1)         30 (37.0)            0.141
   Intestine                                                     11 (52.4)        27 (33.3)            
   Others                                                        2 (9.5)          24 (29.7)            
  Genotype[c](#tfn7-cmar-10-6121){ref-type="table-fn"}                                                 
   C-KIT 11                                                      12 (57.1)        30 (37.0)            0.808
   Others                                                        3 (14.3)         9 (11.1)             
  Metastatic phase                                                                                     
   Synchronous                                                   11 (52.4)        40 (49.4)            0.807
   Metachronous                                                  10 (47.6)        41 (50.6)            
  Response to first-line Imatinib                                                                      
   CR                                                            1 (4.8)          3 (3.7)              0.285
   PR                                                            7 (33.3)         41 (50.6)            
   SD                                                            13 (61.9)        35 (43.2)            
   PD                                                            0 (0)            2 (2.5)              
  Second-line TKI[d](#tfn8-cmar-10-6121){ref-type="table-fn"}                                          
   Yes                                                           16 (76.2)        47 (58.0)            0.127
   No                                                            5 (23.8)         34 (42.0)            

**Notes:**

Radiological reports of 17 patients are not available;

diameter of the largest metastases, data not available in 23 patients;

genotype tests for primary tumor were not performed in 48 patients;

high-dose imatinib or sunitinib.

**Abbreviations:** CR, complete response; PD, progressive disease; PR, partial response; SD, standard disease; TKI, tyrosine kinase inhibitor.

###### 

Patients undergoing metastectomy (n=21)

  Parameters                                                                   n    \%
  --------------------- ------------------------------------------------------ ---- ------
  Preoperative IM                                                                   
                        No                                                     7    33.4
                        Yes                                                    14   66.7
  Surgical procedures                                                               
                        Partial resection                                      11   52.4
                        Partial resection + ablation                           4    19.0
                        Subsegmentectomy                                       3    14.3
                        Segmentectomy                                          3    14.3
                        Segmentectomy + ablation                               2    9.5
  Surgical outcome                                                                  
                        R0                                                     15   71.4
                        NED[a](#tfn10-cmar-10-6121){ref-type="table-fn"}       6    28.6
  Survival outcome                                                                  
                        With tumor                                             6    60.0
                        Death                                                  1    40.0
  Gene mutation                                                                     
                        C-KIT 11                                               11   52.4
                        Unknown[b](#tfn11-cmar-10-6121){ref-type="table-fn"}   10   47.6

**Notes:**

Patients who received ablation concurrently;

patients who were not tested for genotypes.

**Abbreviations:** NED, no evidence of disease; IM, imatinib.

###### 

Correlation of clinicopathological factors with PFS and OS

  Parameters         PFS    OS                                           
  ------------------ ------ ------ ------- ------- ------ ------ ------- -------
  Sex                                                                    
   Male              82.0   85.7   0.059   0.144   84.5   62.2   0.143   --
   Female            NYR    89.4                   NYR    93.3           
  Age (years)                                                            
   \<60              NYR    84.8   0.863   --      NYR    71.8   0.462   --
   ≥60               82.0   92.0                   82.0   59.2           
  Primary sites                                                          
   Stomach           NYR    88.3   0.956   --      NYR    69.3   0.958   --
   Intestine         82.0   88.7                   84.5   72.7           
   Others            NYR    80.8                   NYR    82.3           
  Metastatic phase                                                       
   Synchronous       46     65.4   0.140   --      NYR    57.1   0.239   --
   Metachronous      59     73.2                   NYR    77.0           
  Metastectomy                                                           
   Yes               NYR    77.5   0.027   0.064   NYR    85.7   0.008   0.095
   No                NYR    65.0                   81.0   59.6           
  No of metastases                                                       
   \<3               NYR    72.8   0.019   0.142   NYR    91.7   0.080   0.185
   ≥3                45.0   65.8                   NYR    55.3           

**Abbreviations:** PFS, progression-free survival; OS, overall survival; NYR, not yet reached.
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